-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, China Pharmaceutical and Health Industry Co., Ltd. ("China Pharmaceuticals") issued a "announcement on the purchase of assets and foreign investment by subsidiaries".
China Pharmaceutical Holding Subsidiary China Pharmaceutical Heilongjiang Co., Ltd. ("Heilongjiang Company") intends to invest a total of 91.45 million yuan to control a 51% stake in Qiqihar Zhongrui Pharmaceutical Co., Ltd. ("China-Swiss Medicine").according to the
announcement, before the transaction, the registered capital of China-Swiss Medicine was 99.55 million yuan, of which Qi City SASAC held 44.55 million yuan, accounting for 44.75 percent of its total share capital, and Hongguan Machinery held 55 million yuan, accounting for 55.25 percent of its total share capital.
announced that the current business of Chinese and Swiss medicine to public hospitals pharmaceutical distribution business, in the supply chain management, hospital pharmacy design, cooperation with hospitals, etc. , accumulated a large number of successful experience;
the completion of this transaction, Sino-Swiss Medicine, as a joint venture between the state-owned enterprises and the local SASAC, will actively participate in the reform of the medical system of qiqihar municipal government to meet the supply of medicines and medical supplies in public hospitals. Chinese and Swiss medicine will be the existing public hospital supply chain management business gradually extended to the hospital, the follow-up will be through the integration of the market, the development of county-level and other medical institutions, to obtain a greater market share. As a result, Chinese medicine can expand its industry influence in Heilongjiang Province, increase sales scale, profitability, and increase market competitiveness.
the completion of the transaction, Chinese and Swiss medicine will be included in the scope of China Pharma's consolidated statements, which will increase the total assets, operating income, total profits and other financial indicators of Chinese medicine, the company said in a statement. (China Net)
